Systematic Financial Management LP Makes New $976,000 Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Systematic Financial Management LP acquired a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 8,897 shares of the medical equipment provider's stock, valued at approximately $976,000.

A number of other large investors also recently added to or reduced their stakes in the stock. Sarissa Capital Management LP acquired a new position in Lantheus during the third quarter worth $2,854,000. Point72 DIFC Ltd purchased a new stake in shares of Lantheus during the third quarter worth $23,001,000. Portolan Capital Management LLC grew its holdings in shares of Lantheus by 6.1% during the third quarter. Portolan Capital Management LLC now owns 670,881 shares of the medical equipment provider's stock worth $73,629,000 after buying an additional 38,776 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Lantheus by 7.7% during the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider's stock worth $393,844,000 after buying an additional 257,022 shares in the last quarter. Finally, HighTower Advisors LLC purchased a new stake in shares of Lantheus during the third quarter worth $607,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Price Performance

Shares of LNTH traded down $0.32 during mid-day trading on Friday, reaching $89.02. The stock had a trading volume of 551,654 shares, compared to its average volume of 1,016,929. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The business's fifty day moving average is $99.39 and its 200 day moving average is $97.42. The firm has a market cap of $6.19 billion, a price-to-earnings ratio of 14.81 and a beta of 0.45.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on LNTH shares. JMP Securities dropped their target price on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a report on Thursday, November 7th. StockNews.com lowered shares of Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Truist Financial reaffirmed a "buy" rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, Redburn Atlantic initiated coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 target price for the company. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Lantheus currently has an average rating of "Moderate Buy" and a consensus target price of $130.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.